Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 18/20 | 0.63 |
| ▸ | CCR1 | P32246 | 1/20 | 0.63 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13226258 | 0.93 | CCR2 (0.58) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13226263 | 0.91 | CCR2 (0.57) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13646158 | 0.90 | CCR2 (0.63) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13226465 | 0.90 | CCR2 (0.53) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13226458 | 0.90 | CCR2 (0.59) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13226450 | 0.90 | CCR2 (0.56) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13226324 | 0.89 | CCR2 (0.54) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL18559285 | 0.88 | CCR2 (0.69) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13645960 | 0.87 | CCR2 (0.61) | CCR2CCR1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL13226473 | 0.87 | CCR2 (0.55) | CCR2CCR1TMEM97SIGMAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9579309-B2 | Prophylactic or therapeutic agent for posterior ocular disease containing tetrahydropyranylaminocyclopentylcarbonyltetrahydropyridopyridine derivative as effective ingredient | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2017-02-28 | — | — | US | disclosed |
| EP-2962691-A1 | AGENT FOR PREVENTING OR TREATING DISEASES OF POSTERIOR PART OF THE EYE AND CONTAINING TETRAHYDROPYRANYL AMINO CYCLOPENTYLCARBONYL TETRAHYDROPYRIDOPYRIDINE DERIVATIVE AS ACTIVE COMPONENT | Santen Pharmaceutical Co., Ltd (JP) | 2016-01-06 | — | — | EP | disclosed |
| US-7786305-B2 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786305-B2 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7598243-B2 | inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases | MERCK & CO., INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7566726-B2 | 3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity | MERCK & CO. INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566726-B2 | 3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity | MERCK & CO. INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2008-04-03 | — | — | US | disclosed |
| US-20080021057-A1 | 3-Trifluoromethyl,6-((3-(methyl,4-hydroxytetrahydropyran-4-yl)-amino-(3-isopropyl-cyclopent-1,3-ylene))-carbonyl-)-5,6,7,8-tetrahydro-1,6-naphthyridine; antiinflammatory agents; immunomodulators; antiallergens; rhintis; dermatitis; conjunctivits, asthma; autoimmune diseases; antiarthritis agents | MERCK SHARP & DOHME CORP. | 2008-01-24 | — | — | US | disclosed |
| US-20080021057-A1 | 3-Trifluoromethyl,6-((3-(methyl,4-hydroxytetrahydropyran-4-yl)-amino-(3-isopropyl-cyclopent-1,3-ylene))-carbonyl-)-5,6,7,8-tetrahydro-1,6-naphthyridine; antiinflammatory agents; immunomodulators; antiallergens; rhintis; dermatitis; conjunctivits, asthma; autoimmune diseases; antiarthritis agents | MERCK SHARP & DOHME CORP. | 2008-01-24 | — | — | US | disclosed |
| US-7307086-B2 | 3-(4-heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2007-12-11 | — | — | US | disclosed |
| US-7307086-B2 | 3-(4-heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2007-12-11 | — | — | US | disclosed |
| US-7230008-B2 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK & CO, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230008-B2 | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity | MERCK & CO, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2007-05-24 | — | — | US | disclosed |
| US-20050267146-A1 | 3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117797-A1 | Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity | CCR7, ACKR3, CCR2 | CCR2 3/4885CCR1 4/4885TMEM97 1640/4885 |
| US-20080021057-A1 | 3-Trifluoromethyl,6-((3-(methyl,4-hydroxytetrahydropyran-4-yl)-amino-(3-isopropyl-cyclopent-1,3-ylene))-carbonyl-)-5,6,7,8-tetrahydro-1,6-naphthyridine; antiinflammatory agents; immunomodulators; antiallergens; rhintis; dermatitis; conjunctivits, asthma; autoimmune diseases; antiarthritis agents | CCR7, CCR9, CCR8 | CCR2 11/4885CCR1 8/4885TMEM97 3139/4885 |
| US-20080081803-A1 | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity | CCR1, CCR5, CCR2 | CCR2 3/4885CCR1 1/4885TMEM97 1094/4885 |
| US-20050267146-A1 | 3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | CCR5, CXCR3, CCR2 | CCR2 3/4885CCR1 12/4885TMEM97 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.